No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BGNE240621P135000
- 4.50
- 0.000.00%
15min DelayTrading Apr 25 12:56 ET
0.00High0.00Low
0.00Open4.50Pre Close0 Volume0 Open Interest135.00Strike Price0.00Turnover328.66%IV15.77%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry4.50Extrinsic Value100Contract SizeAmericanOptions Type-0.2202Delta0.0092Gamma34.43Leverage Ratio-3.5665Theta-0.0015Rho-7.58Eff Leverage0.0289Vega
Intraday
- 5D
- Daily
News
Beigene (06160.HK) received 1,686,700 restricted stock units.
Beigene (06160.HK) issued 1.6867 million common shares on June 17, 2024, due to the ownership of restricted share units granted under the equity incentive plan (excluding company directors).
Beigene (06160) issued approximately 1.6867 million shares due to restricted share units being awarded to the beneficiary.
Beigene (06160) announced on June 17, 2024 that approximately 1.6867 million shares were issued due to the allocation of restricted share units under the equity incentive plan, excluding company directors.
Beigene (06160) issued approximately 7.1742 million shares due to the allocation of restricted share units under the equity plan.
Beigene (06160) announced that a total of approximately 7.1742 million shares were issued on June 15th and 16th, 2024 due to the attribution of restricted share units granted under the equity incentive plan.
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma
BeiGene (BGNE) said Friday that preliminary data from a phase 3 study of Brukinsa in combination with venetoclax to treat patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma s
BeiGene to Present New Data From SEQUOIA Study Evaluating BRUKINSA Plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutation Preliminary data suggest promising efficacy and
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
DUBAI, United Arab Emirates--(BUSINESS WIRE)--$BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclud
Comments
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
6
Last week’s PDUFAs:
$BeiGene(BGNE.US$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb(BMY.US$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals(VNDA.US$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
$BeiGene(BGNE.US$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb(BMY.US$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals(VNDA.US$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
20
2
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Eyenovia(EYEN.US$ $Vanda Pharmaceuticals(VNDA.US$ $Mirum Pharmaceuticals(MIRM.US$ $Madrigal Pharmaceuticals(MDGL.US$ $Geron(GERN.US$ $Bristol-Myers Squibb(BMY.US$ $2seventy bio(TSVT.US$ $Legend Biotech(LEGN.US$ $OptiNose(OPTN.US$ $Orchard Therapeutics(ORTX.US$ $Merck & Co(MRK.US$ $Akebia Therapeutics(AKBA.US$ $AstraZeneca(AZN.US$ $Liquidia(LQDA.US$ $Esperion Therapeutics(ESPR.US$ $Regeneron Pharmaceuticals(REGN.US$ $BeiGene(BGNE.US$
$Eyenovia(EYEN.US$ $Vanda Pharmaceuticals(VNDA.US$ $Mirum Pharmaceuticals(MIRM.US$ $Madrigal Pharmaceuticals(MDGL.US$ $Geron(GERN.US$ $Bristol-Myers Squibb(BMY.US$ $2seventy bio(TSVT.US$ $Legend Biotech(LEGN.US$ $OptiNose(OPTN.US$ $Orchard Therapeutics(ORTX.US$ $Merck & Co(MRK.US$ $Akebia Therapeutics(AKBA.US$ $AstraZeneca(AZN.US$ $Liquidia(LQDA.US$ $Esperion Therapeutics(ESPR.US$ $Regeneron Pharmaceuticals(REGN.US$ $BeiGene(BGNE.US$
21
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
6
The research is done by the respective broker and I do not endorse any of them. Just sharing here for information and reading pleasure.
alphaedgeinvest...
$BEIGENE(06160.HK$ $BeiGene(BGNE.US$
alphaedgeinvest...
$BEIGENE(06160.HK$ $BeiGene(BGNE.US$
Read more